MASI:NASDAQMasimo Corporation Analysis

Masimo’s stock is trading just above its short‑term moving averages, signaling a bullish price bias, while the RSI is edging toward overbought territory and the MACD histogram has turned negative, hinting at short‑term weakness.
Fundamentally, the company posts solid revenue growth and healthy gross margins, yet its trailing profit margin remains negative and the current PE ratio sits well above the medical‑device industry average, making the valuation appear stretched. The forward PE suggests some improvement, but the pending cash‑out acquisition by Danaher at roughly the current price introduces both a premium upside and legal‑risk uncertainty, as investor‑rights investigations have surfaced. Combined with a recent downgrade to Market Perform, the stock presents a mixed technical and fundamental picture.